硼替佐米成功治疗与系统性红斑狼疮相关的难治性血栓性血小板减少性紫癜
Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus.
作者信息
Yan Ruyu, Zhou Shuang, Wang Jinuo, Yang Huaxia
机构信息
Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, The Ministry of Education Key Laboratory, Beijing 100730, China.
Department of Rheumatology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
出版信息
Rheumatol Immunol Res. 2022 Dec 31;3(4):208-210. doi: 10.2478/rir-2022-0036. eCollection 2022 Dec.
Thrombotic thrombocytopenic purpura (TTP) is a life- threatening disease that can be secondary to systemic lupus erythematosus (SLE). The fist- line treatments of TTP are steroid, immunosuppressor and plasm exchange (PE). However, some patients may have a poor response to these treatments. Bortezomib is a selective proteasome inhibitor and widely used to treat patients with multiple myeloma (MM). In recent years, bortezomib has been used to treat patients with refractory TTP. Here we report a patient with refractory TTP associated with SLE and had a successful treatment with bortezomib.
血栓性血小板减少性紫癜（TTP）是一种可继发于系统性红斑狼疮（SLE）的危及生命的疾病。TTP的一线治疗方法是使用类固醇、免疫抑制剂和血浆置换（PE）。然而，一些患者可能对这些治疗反应不佳。硼替佐米是一种选择性蛋白酶体抑制剂，广泛用于治疗多发性骨髓瘤（MM）患者。近年来，硼替佐米已被用于治疗难治性TTP患者。在此，我们报告一例与SLE相关的难治性TTP患者，其接受硼替佐米治疗取得成功。
Zotero 插件